Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

Foresight Diagnostics, which provides ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of the PRECISE-HL clinical trial with the University of Washington ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose ...

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-b ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

Promising Leiomyosarcoma Therapies such as Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 11.51%, which has investors questioning if this is right time ...